Skip to main content
Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.

Publisher: Bentham Science Publishers

More about this publication?
Volume 9, Number 7, 2002

Book Reviews

Preface
pp. i-i(1)
Author: Jayaram, H.N.

Favourites:
ADD

Reviews

Chemical Synthesis of Benzamide Riboside
pp. 727-731(5)
Authors: Krohn, K.; Dorner, H.; Zukowski, M.

Favourites:
ADD

The Chemistry of Nicotinamide Adenine Dinucleotide (NAD) Analogues Containing C-Nucleosides Related to Nicotinamide Riboside [1]
pp. 733-741(9)
Authors: Pankiewicz, K.W.; Watanabe, K.A.; Lesiak-Watanabe, K.; Goldstein, B.M.; Jayaram, H.N.

Favourites:
ADD

Studies on the Mechanism of Action of Benzamide Riboside: A Novel Inhibitor of IMP Dehydrogenase
pp. 743-748(6)
Authors: Gharehbaghi, K.; Grunberger, W.; Jayaram, H.N.

Favourites:
ADD
Favourites:
ADD
Favourites:
ADD

Potential Mechanisms of Benzamide Riboside Mediated Cell Death
pp. 765-771(7)
Authors: Polgar, D.; Gfatter, S.; Uhl, M.; Kassie, F.; Leisser, C.; Krupitza, G.; Grusch, M.

Favourites:
ADD

Antitumor Activity of Benzamide Riboside In Vitro and In Vivo
pp. 773-779(7)
Authors: Novotny, L.; Rauko, P.; Yalowitz, J.A.; Szekeres, T.

Favourites:
ADD

Metabolism of the Novel IMP Dehydrogenase Inhibitor Benzamide Riboside
pp. 781-786(6)
Authors: Jager, W.; Salamon, A.; Szekeres, T.

Favourites:
ADD

Toxicity and Efficacy of Benzamide Riboside in Cancer Chemotherapy Models
pp. 787-792(6)
Authors: Jayaram, H.N.; Yalowitz, J.A.; Arguello, F.; GreeneJr, J.F.

Favourites:
ADD

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content